Last Updated on Dec 23, 2021 by Aradhana Gotur

On Thursday, smallcap pharma stock Medicamen Biotech (MBL) hit a new high of Rs. 948.95 on rallying 13% on the BSE. So far in December, the stock has surged 62%, ahead of beginning domestic marketing of its Oncology products. Compared to the MBL, Sensex was up 0.32% thus far in the current month.

A quickly evolving therapy field, Oncology has a variety of novel technologies in the development phase that can drastically alter the treatment paradigm. In 2019, the oncology market was valued at $ 143 bn. It is expected to grow at a CAGR of 12% between 2020 and 2025.

About Medicamen Biotech

MBL has been in the industry for nearly two decades. The company manufactures pharmaceutical formulations—based on betalactum, non-betalactum, and cephalosporin drugs—for domestic and overseas markets. Medicamen Biotech has a diversified clientele, consisting of the public sector and other customers across India, Latin America, and Africa.


In H1 FY 2022, MBL had posted a 57% y-o-y growth in its profit after tax (PAT), which stood at Rs. 8.37 cr. The increase was attributed to healthy operational performance. Further, revenue zoomed 6% y-o-y at Rs. 60.61 cr, and EBITDA margins increased to 21.17% from 16.91%.

Big plans ahead

MBL is preparing for ANDA filing for its oncology products, whose domestic marketing will start from January 2022. A team of 20 experienced professionals will be driving the campaign.

The firm’s Bhiwadi (Beta Lactum) unit has been upgraded, and it is now ready for the EU and Australian markets with new products. The company also awaits a UN audit scheduled for 2021-22.

Aradhana Gotur
1 Comment
Inline Feedbacks
View all comments
55,00,000+ users trust Tickertape for Investment Analysis!
55,00,000+ users trust Tickertape for Investment Analysis!

The blog posts/articles on our platform are purely the author’s personal opinion and do not necessarily represent the views of Anchorage Technologies Private Limited (ATPL) or any of its associates. The content in these posts/articles is for informational and educational purposes only and should not be construed as professional financial advice. Should you need such advice, please consult a professional financial or tax advisor. The content on our platform may include opinions, analysis, or commentary, which are subject to change, without notice, based on market conditions or other factors. Further, the use of any third-party websites or services linked on the website is at the user's discretion and risk. ATPL is not responsible for the content, accuracy, or security of external sites. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The examples and/or securities quoted (if any) are for illustration only and are not recommendatory. Any reliance you place on such information is strictly at your own risk. In no event will ATPL be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

By accessing this platform and its blog section, you acknowledge and agree to the Terms and Conditions of this website, Privacy Policy and Disclaimer.